0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Sign in

Purchase Options

• Subscribe to the journal

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Editor's Note  | 
Targeted Reduction in Body Mass Index Is a Worthwhile Risk Reduction Strategy for Prostate Cancer
Charles R. Thomas Jr, MD
JAMA Oncology
Original Investigation  | 
Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Wendy E. Barrington, PhD; Jeannette M. Schenk, PhD; Ruth Etzioni, MD; et al.
JAMA Oncology
Invited Commentary  | 
Effect of 5α-Reductase Inhibitor Use on Mortality From Prostate Cancer
William D. Figg, PharmD, MBA; Ian M. Thompson, MD
JAMA Oncology
Original Investigation  | 
5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer
Laurent Azoulay, PhD; Maria Eberg, MSc; Serge Benayoun, MD, MSc; et al.